BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2116 related articles for article (PubMed ID: 32385712)

  • 1. Inflammation resolution: a dual-pronged approach to averting cytokine storms in COVID-19?
    Panigrahy D; Gilligan MM; Huang S; Gartung A; Cortés-Puch I; Sime PJ; Phipps RP; Serhan CN; Hammock BD
    Cancer Metastasis Rev; 2020 Jun; 39(2):337-340. PubMed ID: 32385712
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Eicosanoids: The Overlooked Storm in Coronavirus Disease 2019 (COVID-19)?
    Hammock BD; Wang W; Gilligan MM; Panigrahy D
    Am J Pathol; 2020 Sep; 190(9):1782-1788. PubMed ID: 32650004
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of sEH inhibition on the eicosanoid and cytokine storms in SARS-CoV-2-infected mice.
    Edin ML; Gruzdev A; Graves JP; Lih FB; Morisseau C; Ward JM; Hammock BD; Bosio CM; Zeldin DC
    FASEB J; 2024 May; 38(10):e23692. PubMed ID: 38786655
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Baricitinib, a drug with potential effect to prevent SARS-COV-2 from entering target cells and control cytokine storm induced by COVID-19.
    Zhang X; Zhang Y; Qiao W; Zhang J; Qi Z
    Int Immunopharmacol; 2020 Sep; 86():106749. PubMed ID: 32645632
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Contribution of monocytes and macrophages to the local tissue inflammation and cytokine storm in COVID-19: Lessons from SARS and MERS, and potential therapeutic interventions.
    Jafarzadeh A; Chauhan P; Saha B; Jafarzadeh S; Nemati M
    Life Sci; 2020 Sep; 257():118102. PubMed ID: 32687918
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Possibility of averting cytokine storm in SARS-COV 2 patients using specialized pro-resolving lipid mediators.
    Yasmeen N; Selvaraj H; Lakhawat SS; Datta M; Sharma PK; Jain A; Khanna R; Srinivasan J; Kumar V
    Biochem Pharmacol; 2023 Mar; 209():115437. PubMed ID: 36731803
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Specialized pro-resolving mediator network: an update on production and actions.
    Chiang N; Serhan CN
    Essays Biochem; 2020 Sep; 64(3):443-462. PubMed ID: 32885825
    [TBL] [Abstract][Full Text] [Related]  

  • 8. COVID-19 and cancer: start the resolution!
    Barksdale C; Kipper FC; Tripathy S; Subbian S; Serhan CN; Panigrahy D
    Cancer Metastasis Rev; 2022 Mar; 41(1):1-15. PubMed ID: 35190921
    [TBL] [Abstract][Full Text] [Related]  

  • 9.
    Siddiqui R; Khan NA
    ACS Chem Neurosci; 2020 Aug; 11(16):2391-2392. PubMed ID: 32786329
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Specialized pro-resolving lipid mediators regulate inflammatory macrophages: A paradigm shift from antibiotics to immunotherapy for mitigating COVID-19 pandemic.
    Kumar V; Yasmeen N; Chaudhary AA; Alawam AS; Al-Zharani M; Suliman Basher N; Harikrishnan S; Goud MD; Pandey A; Lakhawat SS; Sharma PK
    Front Mol Biosci; 2023; 10():1104577. PubMed ID: 36825200
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The COVID-19 Cytokine Storm; What We Know So Far.
    Ragab D; Salah Eldin H; Taeimah M; Khattab R; Salem R
    Front Immunol; 2020; 11():1446. PubMed ID: 32612617
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Harnessing the immune system to overcome cytokine storm and reduce viral load in COVID-19: a review of the phases of illness and therapeutic agents.
    Khadke S; Ahmed N; Ahmed N; Ratts R; Raju S; Gallogly M; de Lima M; Sohail MR
    Virol J; 2020 Oct; 17(1):154. PubMed ID: 33059711
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Commentary: Phosphodiesterase 4 inhibitors as potential adjunct treatment targeting the cytokine storm in COVID-19.
    Dalamaga M; Karampela I; Mantzoros CS
    Metabolism; 2020 Aug; 109():154282. PubMed ID: 32497535
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tackling the cytokine storm in COVID-19, challenges and hopes.
    Abdin SM; Elgendy SM; Alyammahi SK; Alhamad DW; Omar HA
    Life Sci; 2020 Sep; 257():118054. PubMed ID: 32663575
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The case for chronotherapy in Covid-19-induced acute respiratory distress syndrome.
    Tamimi F; Abusamak M; Akkanti B; Chen Z; Yoo SH; Karmouty-Quintana H
    Br J Pharmacol; 2020 Nov; 177(21):4845-4850. PubMed ID: 32442317
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Society for Immunotherapy of Cancer perspective on regulation of interleukin-6 signaling in COVID-19-related systemic inflammatory response.
    Arnaldez FI; O'Day SJ; Drake CG; Fox BA; Fu B; Urba WJ; Montesarchio V; Weber JS; Wei H; Wigginton JM; Ascierto PA
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32385146
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mast cells activated by SARS-CoV-2 release histamine which increases IL-1 levels causing cytokine storm and inflammatory reaction in COVID-19.
    Conti P; Caraffa A; Tetè G; Gallenga CE; Ross R; Kritas SK; Frydas I; Younes A; Di Emidio P; Ronconi G
    J Biol Regul Homeost Agents; 2020 Sep-Oct,; 34(5):1629-1632. PubMed ID: 32945158
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IL-15 immunotherapy is a viable strategy for COVID-19.
    Kandikattu HK; Venkateshaiah SU; Kumar S; Mishra A
    Cytokine Growth Factor Rev; 2020 Aug; 54():24-31. PubMed ID: 32536564
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of Interleukin 6 inhibitors in therapy of severe COVID-19.
    Nasonov E; Samsonov M
    Biomed Pharmacother; 2020 Nov; 131():110698. PubMed ID: 32920514
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rationale for targeting complement in COVID-19.
    Polycarpou A; Howard M; Farrar CA; Greenlaw R; Fanelli G; Wallis R; Klavinskis LS; Sacks S
    EMBO Mol Med; 2020 Aug; 12(8):e12642. PubMed ID: 32559343
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 106.